Faes Farma SA - Company Profile
Powered by 
All the sales intelligence you need on Faes Farma SA in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Faes Farma SA fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Faes Farma SA.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Faes Farma SA (Faes Farma) engages in the research, development, manufacturing, and marketing of prescription medicines, healthcare products, and animal nutrition products. The company focuses on various therapeutic areas such as allergic diseases, gastrointestinal diseases, bone immunomodulation, and pain. The company offers medicines, active substances, cosmetic products, food supplements, nutritional products, and medical devices. It also offers complementary feeds (concentrates), correctors, complete feeds, and supplements for pigs, ruminants, poultry, and aquaculture. Faes Farma offers its products to food and feed customers, including agricultural companies, distributors, and feed manufacturers. The company operates production plants in Spain, Guatemala, and Portugal. It markets the products in Latin America, Asia, Europe, Africa, and the Middle East. Faes Farma is headquartered in Leioa, Spain.
Headquarters
Spain
Address
Avda. Autonomia 10, Leioa, Vizcaya, 48940
Website
www.faesfarma.com
Telephone
34 944 818301
No of Employees
2,671
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
FAE (MCE)
Revenue (2024)
$688.7M
23.7%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-28.5%
(2024 vs 2023)
Market Cap*
$1.8B
Net Profit Margin (2024)
XYZ
-42.2%
(2024 vs 2023)
* As of and is in US$
Faes Farma SA premium industry data and analytics
Products and Services
| Products |
|---|
| Active Ingredients: |
| Diosmine (CEP) |
| Diosmine Micronized (CEP) |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Acquisitions/Mergers/Takeovers | In September, the company acquired SIFI, an ophthalmology firm. |
| 2025 | Acquisitions/Mergers/Takeovers | In June, the company acquired Laboratorios Edol Produtos Farmaceuticos, S.A., a firm specializing in ophthalmology. |
| 2024 | Others | In February, the company introduced its new corporate website. |
Competitor Comparison
| Key Parameters | Faes Farma SA | Grifols SA | Almirall SA | Laboratorios Farmaceuticos Rovi SA | Laboratorios Richmond SACIF |
|---|---|---|---|---|---|
| Headquarters | Spain | Spain | Spain | Spain | Argentina |
| City | Leioa | Sant Cugat Del Valles | Barcelona | Madrid | Buenos Aires |
| State/Province | Vizcaya | Barcelona | Barcelona | Madrid | Ciudad Autonoma De Buenos Aires |
| No. of Employees | 2,671 | 23,822 | 2,084 | 2,232 | - |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Iker Etxezarreta | Chief Financial Officer | Senior Management | 2025 | - |
| Isabel Najera | Chief Scientific Officer | Senior Management | 2025 | - |
| D.Eduardo Recoder de la Cuarda | Chief Executive Officer; Executive Director | Executive Board | 2024 | - |
| Carlos Gutirrrez | Chief People Officer | Senior Management | - | - |
| Xavier Arnaud | Chief Business Development Officer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer